Ilse Vanhorebeek

Ilse Vanhorebeek

Auto-generated profile, based on publicly available information

Ilse Vanhorebeek

Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2020 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
IVIlse Vanhorebeek
Ilse Vanhorebeek
NLNicola LATRONICO
Nicola LATRONICO
GBGreet Van den Berghe
Greet Van den Berghe

13 June 2006 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LRLars Rydén
Lars Rydén
ESEberhard Standl
Eberhard Standl
MBMałgorzata Bartnik
Małgorzata Bartnik
GBGreet Van den Berghe
Greet Van den Berghe
JBJohn Betteridge
John Betteridge
DWDavid Wood
David Wood
Guidelines and Expert Consensus documents aim to present management and recommendations based on all of the relevant evidence on a particular subject in order to help physicians to select the best possible management strategies for the individual patient, suffering from a specific condition, taking into account not only the impact on outcome, but also the risk benefit ratio of a particular diagnostic or therapeutic procedure. The ESC recommendations for guidelines production can be found on the ESC website†.

27 August 2009 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DPDon Poldermans
Don Poldermans
JBJeroen J. Bax
Jeroen J. Bax
EBEric Boersma
Eric Boersma
SHStefan De Hert
Stefan De Hert
EEErik Eeckhout
Erik Eeckhout
MTMarco Tubaro
Marco Tubaro
Guidelines and Expert Consensus Documents aim to present management and recommendations based on the relevant evidence on a particular subject in order to help physicians to select the best possible management strategies for the individual patient suffering from a specific condition, taking into account not only the impact on outcome, but also the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously.1

18 April 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EBEva Boonen
Eva Boonen
HVHilke Vervenne
Hilke Vervenne
PMPhilippe Meersseman
Philippe Meersseman
RARuth Andrew
Ruth Andrew
LMLeen Mortier
Leen Mortier
GBGreet Van den Berghe
Greet Van den Berghe
Critical illness is often accompanied by hypercortisolemia, which has been attributed to stress-induced activation of the hypothalamic–pituitary–adrenal axis. However, low corticotropin levels have also been reported in critically ill patients, which may be due to reduced cortisol metabolism. In a total of 158 patients in the intensive care unit and 64 matched controls, we tested five aspects of cortisol metabolism: daily levels of corticotropin and cortisol; plasma cortisol clearance, metabolism, and production during infusion of deuterium-labeled steroid hormones as tracers; plasma clearance of 100 mg of hydrocortisone; levels of urinary cortisol metabolites; and levels of messenger RNA and protein in liver and adipose tissue, to assess major cortisol-metabolizing enzymes. Total and free circulating cortisol levels were consistently higher in the patients than in controls, whereas corticotropin levels were lower (P<0.001 for both comparisons). Cortisol production was 83% higher in the patients (P=0.02). There was a reduction of more than 50% in cortisol clearance during tracer infusion and after the administration of 100 mg of hydrocortisone in the patients (P≤0.03 for both comparisons). All these factors accounted for an increase by a factor of 3.5 in plasma cortisol levels in the patients, as compared with controls (P<0.001). Impaired cortisol clearance also correlated with a lower cortisol response to corticotropin stimulation. Reduced cortisol metabolism was associated with reduced inactivation of cortisol in the liver and kidney, as suggested by urinary steroid ratios, tracer kinetics, and assessment of liver-biopsy samples (P≤0.004 for all comparisons). During critical illness, reduced cortisol breakdown, related to suppressed expression and activity of cortisol-metabolizing enzymes, contributed to hypercortisolemia and hence corticotropin suppression. The diagnostic and therapeutic implications for critically ill patients are unknown. (Funded by the Belgian Fund for Scientific Research and others; ClinicalTrials.gov numbers, NCT00512122 and NCT00115479; and Current Controlled Trials numbers, ISRCTN49433936, ISRCTN49306926, and ISRCTN08083905.)

24 March 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
TFTom Fivez
Tom Fivez
DKDorian Kerklaan
Dorian Kerklaan
DMDieter Mesotten
Dieter Mesotten
SVSascha Verbruggen
Sascha Verbruggen
PWPieter J. Wouters
Pieter J. Wouters
GBGreet Van den Berghe
Greet Van den Berghe
Recent trials have questioned the benefit of early parenteral nutrition in adults. The effect of early parenteral nutrition on clinical outcomes in critically ill children is unclear. We conducted a multicenter, randomized, controlled trial involving 1440 critically ill children to investigate whether withholding parenteral nutrition for 1 week (i.e., providing late parenteral nutrition) in the pediatric intensive care unit (ICU) is clinically superior to providing early parenteral nutrition. Fluid loading was similar in the two groups. The two primary end points were new infection acquired during the ICU stay and the adjusted duration of ICU dependency, as assessed by the number of days in the ICU and as time to discharge alive from ICU. For the 723 patients receiving early parenteral nutrition, parenteral nutrition was initiated within 24 hours after ICU admission, whereas for the 717 patients receiving late parenteral nutrition, parenteral nutrition was not provided until the morning of the 8th day in the ICU. In both groups, enteral nutrition was attempted early and intravenous micronutrients were provided. Although mortality was similar in the two groups, the percentage of patients with a new infection was 10.7% in the group receiving late parenteral nutrition, as compared with 18.5% in the group receiving early parenteral nutrition (adjusted odds ratio, 0.48; 95% confidence interval [CI], 0.35 to 0.66). The mean (±SE) duration of ICU stay was 6.5±0.4 days in the group receiving late parenteral nutrition, as compared with 9.2±0.8 days in the group receiving early parenteral nutrition; there was also a higher likelihood of an earlier live discharge from the ICU at any time in the late-parenteral-nutrition group (adjusted hazard ratio, 1.23; 95% CI, 1.11 to 1.37). Late parenteral nutrition was associated with a shorter duration of mechanical ventilatory support than was early parenteral nutrition (P=0.001), as well as a smaller proportion of patients receiving renal-replacement therapy (P=0.04) and a shorter duration of hospital stay (P=0.001). Late parenteral nutrition was also associated with lower plasma levels of γ-glutamyltransferase and alkaline phosphatase than was early parenteral nutrition (P=0.001 and P=0.04, respectively), as well as higher levels of bilirubin (P=0.004) and C-reactive protein (P=0.006). In critically ill children, withholding parenteral nutrition for 1 week in the ICU was clinically superior to providing early parenteral nutrition. (Funded by the Flemish Agency for Innovation through Science and Technology and others; ClinicalTrials.gov number, NCT01536275.)

1 February 2009 in The Lancet
Verified
Journal Article
Closed access
DVDirk Vlasselaers
Dirk Vlasselaers
IMIlse Milants
Ilse Milants
LDLars Desmet
Lars Desmet
PWPieter J Wouters
Pieter J Wouters
IVIlse Vanhorebeek
Ilse Vanhorebeek
GBGreet Van den Berghe
Greet Van den Berghe